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Abstract
Background: Peripheral arterial disease (PAD) is common in patients with end-stage renal disease on hemodialysis,
but is frequently underdiagnosed. The risk factors for PAD are well known within the general population, but they
differ somewhat in hemodialysis patients. This study aimed to determine the prevalence of PAD and its risk factors
in patients on hemodialysis.
Methods: This cross-sectional study included 156 hemodialysis patients. Comorbidities and laboratory parameters
were analyzed. Following clinical examinations, the ankle-brachial index was measured in all patients. PAD was
diagnosed based on the clinical findings, ankle-brachial index < 0.9, and PAD symptoms.
Results: PAD was present in 55 of 156 (35.3%; 95% CI, 27.7–42.8%) patients. The patients with PAD were
significantly older (67 ± 10 years vs. 62 ± 11 years, p = 0.014), more likely to have diabetes mellitus (p = 0.022),
and anemia (p = 0.042), and had significantly lower serum albumin (p = 0.005), total cholesterol (p = 0.024), and
iron (p = 0.004) levels, higher glucose (p = 0.002) and C-reactive protein (p < 0.001) levels, and lower dialysis
adequacies (p = 0.040) than the patients without PAD. Multivariate analysis showed higher C-reactive protein
level (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.00–1.06; p = 0.030), vascular access by Hickman
catheter (OR, 4.66; 95% CI, 1.03–21.0; p = 0.045), and symptoms of PAD (OR, 5.20; 95% CI, 2.60–10.4; p < 0.001)
as independent factors associated with PAD in hemodialysis patients.
Conclusion: The prevalence of PAD was high among patients with end-stage renal disease on hemodialysis.
Symptoms of PAD, higher C-reactive protein levels, and Hickman vascular access were independent predictors
of PAD in patients on hemodialysis.
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Introduction
Peripheral arterial disease (PAD) of the lower extremities
is widespread, and it affects over 200 million people
worldwide [1]. PAD is also highly prevalent among pa-
tients with end-stage renal disease, and it has serious
consequences that influence patient outcomes [2, 3].
The prevalence of PAD has increased over the last
decade, particularly in low-income countries [4]; further,
it increases with age and is 4.5–14.5% more prevalent
among individuals aged ≥65 years [5]. Among patients
on hemodialysis (HD), the prevalence of PAD is much
higher, ranging from 17 to 48% [6, 7].
The findings from the Dialysis Outcomes and Practice
Patterns Study (DOPPS) described a PAD prevalence of
25.3% among patients on HD that was accompanied by
significant geographic variations. In European countries,
PAD prevalence was 17.5–37.8%, while in Japan¸ the
prevalence was significantly lower at 11.5% [8]. Similarly,
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the findings from the Hemodialysis Study (HEMO)
showed that PAD was seen in 23% of patients on HD
[9]. The findings from the National Health and Nutrition
Examination Survey (NHANES) 1999–2000 showed that
PAD was present in 24% of patients with renal insuffi-
ciency and in 3.7% of participants with normal renal
function; these findings were independent of diabetes,
age, and hypertension [10]. Japanese investigators have
shown that PAD prevalence in patients on HD ranges
from 23.8 to 47%, depending on the study population
[2, 11]. Although these studies were valuable, they
had different methods for PAD diagnosis.
The early diagnosis and management of PAD can
improve the prognosis for patients on HD [11].
Therefore, many patients on HD with PAD could
avoid or at least delay adverse events, such as ampu-
tations, cardiovascular events, and death if PAD was
timely diagnosed and adequately treated [12]. The
traditional risk factors for PAD, namely, age, diabetes
mellitus (DM), smoking, hyperlipidemia, hyperten-
sion, and male sex, are well recognized within the
general population [7], but these risk factors are
supplemented by other risk factors in patients on
HD [13, 14]. To our knowledge, no studies have pre-
viously investigated the effects of vascular access on
PAD prevalence. Thus, this study aimed to examine
the prevalence of PAD, the risk factors associated
with PAD, and the clinical characteristics of PAD in
patients on HD.
Methods
Study population
The study subjects comprised 197 outpatients who were
on maintenance HD at the Clinical Department for
Nephrology and Metabolic Disorders with Dialysis at
Zvezdara University Medical Center. Of these subjects,
41 patients were excluded from the study because 36 did
not provide informed consent and five died during the
study and their data were incomplete. Hence, 156 pa-
tients participated in this cross-sectional study between
January 2016 and January 2017. Zvezdara University
Medical Center’s ethics committee approved this study,
and all participants provided written informed consent
before study initiation.
Risk factors and comorbid diseases
The patients’ medical records were reviewed, and data
describing their demographic and clinical characteristics
were collected, including age, sex, height, weight, HD
duration and type, and causes of renal failure. The fol-
lowing risk factors and comorbidities associated with
PAD were analyzed: smoking habits, hypertension,
hyperlipidemia, DM, anemia, coronary artery disease,
and cerebrovascular diseases, including stroke. The body
mass index was calculated as the weight in kilograms di-
vided by height in meters squared.
Laboratory parameters
Blood samples were taken quarterly at the beginning of
the second HD session of the week. The analyzed la-
boratory parameters included the serum creatinine, urea,
potassium, calcium, albumin, phosphorus, total choles-
terol, triglyceride, glucose, C-reactive protein (CRP),
iron, transferrin saturation, ferritin, intact parathyroid
hormone, dialysis adequacy (Kt/V), hemoglobin levels
and blood cell counts. Mean values of four measure-
ments were used in the analyses.
Patient assessments and clinical examinations
Blood pressure measurements were obtained before
and after dialysis and during three consecutive dialysis
sessions, and the mean values were used to calculate
the pulse pressure (systolic pressure – diastolic pres-
sure) and the mean arterial pressure (diastolic pres-
sure + 1/3 pulse pressure). The presence of left
ventricular hypertrophy was determined indirectly
using electrocardiography.
The patients’ histories of previous peripheral artery in-
terventions, including bypass surgery, percutaneous in-
terventions, or amputations for PAD, were documented.
The patients were asked about PAD symptoms, includ-
ing claudication, coldness, numbness, and resting pain,
and they were categorized using the Fontaine classifica-
tion of PAD symptoms [15].
All patients underwent standard physical examinations
that included pulse palpation on the femoral artery, pop-
liteal artery, dorsalis pedis artery, and posterior tibial ar-
tery on both legs, and auscultation for femoral bruits.
The pulses were coded as absent (0), weak (1), or
present (2). To ensure that the findings were compar-
able, all patients were examined by the same experienced
physician.
Ankle-brachial index (ABI) measurements
We measured ABI using a portable handheld bidirec-
tional Doppler device (Life Dop 250 ABI; Wallach Surgi-
cal Devices, Trumbull, CT, USA). All ABIs were
measured at room temperature and before dialysis while
the patients were unclothed, in a supine position, and
after they had rested for 5–10min. The systolic blood
pressure was measured in the brachial artery of the arm
without vascular access and in the dorsalis pedis artery
and posterior tibial artery of the right and left lower
limbs after using a Doppler probe of appropriate cuff
size. The same well-trained nurse performed all ABI
measurements. The ABI was calculated by dividing the
ankle systolic pressure by arm systolic pressure. The
lower ABI value of both legs was used as the leg index.
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An ABI was classified as low (< 0.9) if any of the ABI
values were < 0.9, normal (0.9–1.3) if all four values were
between 0.9 and 1.3, and high (> 1.3) if at least one ABI
was > 1.3 with other values being normal [16].
Patients were diagnosed with PAD if they fulfilled the
criteria relating to clinical examinations, Fontaine classi-
fication, and ABIs. The patients were considered to have
PAD if they had an ABI < 0.9 or if they had claudication
and absence of pulses, despite having normal ABIs. We
performed duplex ultrasonography on patients who had
normal and high ABIs, and confirmed PAD if there was
≥50% narrowing of the large lower extremity blood ves-
sels that had caused either sub-occlusion or occlusion of
≥1 crural arteries.
Statistical analyses
The R software environment for statistical computing [17]
was used to conduct the statistical analyses. The signifi-
cance level was set at 0.05. Continuous variables are pre-
sented as the means and standard deviations, and
categorical variables are presented as numbers and per-
centages; these descriptive statistics were used to
characterize the study sample. The differences between
groups in relation to the continuous variables were ana-
lyzed using Student’s t-test and the Mann–Whitney U test
for the independent samples. Pearson’s chi-squared test or
Fisher’s exact test were used to analyze the differences be-
tween groups in relation to the categorical variables. A
multivariate logistic regression model was constructed to
determine the predictors of PAD, which included the sta-
tistically significant variables (P < 0.05) from the univariate
analyses.
Results
There were no statistically significant differences be-
tween patients who did and did not participate in the
study in terms of age, sex, and HD vintage. Of the 156
patients identified, PAD was present in 55 (35.3%; 95%
CI, 27.7–42.8%), of which 40% were women (Table 1).
Hypertension was the most common condition that
caused the end-stage renal disease (53.2%), and DM was
the second most common cause of the end-stage renal
disease (12.8%) in our patients. Compared with the non-
PAD group, the PAD patients were older, more likely to
be male, and had higher incidence rates of anemia and
DM. The participants’ mean HD vintage was 71.7 ± 69.5
(median: 55; range: 0–354) months. The groups did not
differ in relation to the HD type and daily HD duration.
Type of vascular access significantly differed between
the PAD and non- PAD groups (p = 0.004). The preva-
lence of PAD was the highest in patients with Hickman
vascular catheter (75%), followed by patients with
arteriovenous graft (AVG; 53.8%), and was the lowest in
patients with arteriovenous fistula (AVF; 30%). The only
statistically significant difference in PAD prevalence
between these groups was found when patients with
Hickman vascular catheter and AVF were compared
(p = 0.003). Although the prevalence of PAD was greater
in patients with AVG than in those with AVF, there was
no significant difference (p = 0.117).
The PAD group had a lower median Kt/V value
than the non-PAD group (1.31 [range: 0.82–2.14] vs.
1.37 [range: 0.51–3.34]; p = 0.04). Two patients had
undergone major amputations as a consequence of
PAD; specifically, one had above-the-knee amputation
and one had below-the-knee amputation. Four
patients had undergone minor amputations, compris-
ing two who had amputations of one toe and two
who had amputations of a little toe. One patient had
undergone an abdominal aortic aneurysm resection
and another patient had undergone a femoro-femoral
cross-over bypass. The patients in the PAD and non-
PAD groups did not differ in relation to the systolic
blood pressure, diastolic blood pressure, pulse pres-
sure, and mean arterial pressure values determined
before and after HD.
The prevalence of PAD was associated with the age of
patients on HD, and it was most prevalent among pa-
tients who were ≥ 80 years old (Fig. 1).
Table 2 presents the participants’ symptoms and clin-
ical findings. Of the patients on HD without PAD, 19.8%
had various symptoms in their legs, including coldness
and numbness, and 2% had claudications. The PAD and
non-PAD groups differed significantly in relation to the
clinical findings, including pulse palpation, femoral bruit
auscultation, and ABI values (all p < 0.001).
The patients on HD with PAD had significantly lower
median ABIs than the patients on HD without PAD
(0.90 vs. 1.13; p < 0.001) (Fig. 2).
Table 3 summarizes the laboratory blood test results.
The albumin, total cholesterol, and iron levels were
lower and the glucose and CRP levels were higher in the
PAD group than in the non-PAD group.
Table 4 presents the results of logistic regression
analyses using PAD as the dependent variable. The
univariate analysis indicated that age, DM, symptoms
based on the Fontaine classification, vascular access
provided by a Hickman catheter, lower albumin and
total cholesterol levels, and a higher CRP level were
associated with PAD (all p < 0.05). The multivariate
logistic regression analysis showed that the independ-
ent factors associated with PAD in patients on HD
were a higher CRP level (odds ratio [OR], 1.03; 95%
confidence interval [CI], 1.00–1.06; p = 0.030), vascu-
lar access provided by a Hickman catheter (OR, 4.66;
95% CI, 1.03–21.0; p = 0.045), and presence of PAD
symptoms based on the Fontaine classification (OR,
5.20; 95% CI, 2.60–10.4; p < 0.001).
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Table 1 Demographic, baseline and dialysis characteristics of the study population
Characteristics Total PAD No PAD p
156 (100) 55 (35.3) 101 (64.7)
Age years mean ± SD 64 ± 11 67 ± 10 62 ± 11 0.014
Gender, n (%) 0.905
Male, n (%) 96 (61.5) 33 (60.0) 63 (62.4)
Primary kidney disease, n (%) 0.118
Hypertension 83 (53.2) 28 (50.9) 55 (54.5)
Diabetes mellitus 20 (12.8) 12 (21.8) 8 (7.9)
Glomerulonephritis 18 (11.5) 4 (7.3) 14 (13.9)
Cystic disease 12 (7.7) 2 (3.6) 10 (9.9)
Pyelonephritis and Obstructive uropathy 10 (6.4) 4 (7.3) 6 (5.9)
Other 13 (8.3) 5 (9.1) 8 (7.9)
BMI, mean ± SD kg/m2 24.0 ± 4.1 24.2 ± 4.2 23.9 ± 4.0 0.68
Hypertension, n (%) 142 (91.0) 53 (96.4) 89 (88.1) 0.14
Hyperlipoproteinemia, n (%) 75 (48.1) 22 (40.0) 53 (52.5) 0.136
Diabetes mellitus, n (%) 0.022
No 117 (75.0) 34 (61.8) 83 (82.2)
Type II oral therapy 16 (10.3) 8 (14.5) 8 (7.9)
Type II Insulin 20 (12.8) 12 (21.8) 8 (7.9)
Type I Insulin 3 (1.9) 1 (1.8) 2 (2.0)
CAD, n (%) 54 (34.6) 20 (36.4) 34 (33.7) 0.801
Angina pectoris, n (%) 45 (28.8) 15 (27.3) 30 (29.7) 0.750
Myocardial infarction, n (%) 14 (9.0) 8 (14.8) 6 (5.9) 0.081
CABG, PCI, n (%) 15 (9.6) 8 (14.8) 7 (6.9) 0.153
Stroke n (%) 6 (3.8) 4 (7.3) 2 (2.0) 0.186
Anemia, n (%) 144 (92.3) 54 (98.2) 90 (89.1) 0.042
Smoking, n (%) 0.677
No 82 (52.6) 27 (49.1) 55 (54.5)
Yes 39 (25.0) 16 (29.1) 23 (22.8)
Past 35 (22.4) 12 (21.8) 23 (22.8)
LVH, n (%) 17 (10.9) 5 (9.8) 12 (12.9) 0.582
Access for HD, n (%) 0.004
AVF 130 (83.3) 39 (70.9) 91 (90.1)
CVC 1 (0.6) 0 (0.0) 1 (1.0)
Hickman vascular catheter 12 (7.7) 9 (16.4) 3 (3.0)
AVG 13 (8.3) 7 (12.7) 6 (5.9)
HD vintage (months), median (range) 55 (0, 354) 55 (0, 264) 55 (0, 354) 0.867
Type of HD, n (%) 0.086
HDF 29 (18.6) 6 (10.9) 23 (22.8)
High flux HD 127 (81.4) 49 (89.1) 78 (77.2)
Kt/V median (range) 1.34 (0.51, 3.35) 1.31 (0.82, 2.14) 1.37 (0.51, 3.34) 0.040
AVF Arteriovenous fistula, AVG Arteriovenous graft, BMI Body mass index, CAD Coronary artery disease, CABG coronary artery bypass graft, CVC Central venous
catheter, HD Hemodialysis, HDF Hemodiafiltration, LVH Left ventricular hypertrophy, PAD Peripheral arterial disease, PCI Percutaneous coronary intervention
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Discussion
Approximately 35% of patients on HD in this study had
PAD, which concurs with the rates published to date [6, 7].
In this study, PAD was diagnosed based on an ABI of < 0.9,
clinical findings, and categorization of symptoms based on
the Fontaine classification; 41 patients with PAD had ABI
values < 0.9, seven patients had ABI values > 1.3, and seven
had ABI values between 0.9 and 1.3, or more specifically,
between 0.91 and 1.0. We confirmed PAD in seven patients
with normal and in seven patients with high ABI values
using color Doppler ultrasonography. There were signifi-
cant differences between the PAD and non-PAD groups
with respect to the clinical findings, including those from
pulse palpation and femoral bruit auscultation, and ABIs.
The clinical findings were noticeably worse in the PAD
group than in the non-PAD group. Often, these patients
have DM; chronic kidney disease alone leads to arterial in-
compatibility as a consequence of pronounced calcification,
and arterial stiffness generates false-positive ABIs [2, 6, 16].
An ABI < 0.9 alone should not be used to assess the severity
of PAD in patients on HD [2]. An ABI of < 0.9, in conjunc-
tion with the clinical findings, namely, absence of pulses
and presence of femoral bruits, and PAD symptoms, in-
cluding claudication, would provide a more robust founda-
tion for a diagnosis of PAD.
Measuring the ABI is simple, reliable, inexpensive,
and non-invasive [18]. According to the most recent
American Heart Association guidelines, ABIs of 0.9–
1.09 are lower normal values [18]; however, some
Japanese authors have recommended ABIs of 1.05–
1.1 as the limit for a diagnosis of PAD in patients
on HD [2, 11].
Intermittent claudication is the classic and most
striking symptom associated with PAD, and it is rela-
tively rare in the general population and in patients
on HD [5, 19]. Therefore, intermittent claudication
alone is not a reliable criterion for a diagnosis of
PAD [6]. The findings from preliminary studies have
shown that 20–50% of patients with PAD who had
ABIs of < 0.9 did not report claudication; hence, these
patients belong to the asymptomatic group of patients
with PAD [5, 20]. In the UK, Webb et al. [21] studied
325 patients receiving HD and reported that 19% of
these patients had claudication. In this study, 37.2%
of the patients had claudication. In the DOPPS and
Fig. 1 Prevalence of peripheral arterial disease in the hemodialysis
patients according to age. X title: Age (years). Y title: Prevalence (%)
Table 2 Fontaine symptoms and the study participants’ clinical
findings
Total PAD No PAD P
PAD Symptoms Fontaine, n (%)
I 96 (61.5) 15 (27.3) 81 (80.2) <0.001
IIa 37 (23.7) 19 (34.5) 18 (17.8)
IIb 21 (13.5) 19 (34.5) 2 (2.0)
III 1 (0.6) 1 (1.8) 0 (0.0)
IV 1 (0.6) 1 (1.8) 0 (0.0)
Femoral bruit, n (%)
Yes 45 (28.9) 28 (50.9) 17 (16.8) <0.001
No 106 (67.9) 23 (41.8) 83 (82.2)
Pulse, n (%)
Femoral
No 1 (0.6) 1 (1.8) 0 (0) 0.042
Weak 2 (1.3) 2 (3.6) 0 (0)
Yes 153 (98.1) 52 (94.5) 101 (100)
Popliteal
No 22 (14.1) 22 (40.0) 0 (0) <0.001
Weak 8 (5.1) 7 (12.7) 1 (1)
Yes 126 (80.8) 26 (47.3) 100 (99)
DPA
No 46 (29.5) 37 (67.3) 9 (8.9) <0.001
Weak 31 (19.9) 9 (16.4) 22 (21.8)
Yes 79 (50.6) 9 (16.4) 70 (69.3)
PTA
No 50 (32.1) 41 (74.5) 9 (8.9) <0.001
Weak 39 (25.0) 11 (20.0) 28 (27.7)
Yes 67 (42.9) 3 (5.5) 64 (63.4)
ABI indexes n (%)
ABI < 0.9 41 (26.3) 41 (74.5) 0 (0.0) <0.001
ABI > 1.3 36 (23.1) 7 (12.7) 29 (28.7)
ABI 0.91–1.3 79 (50.6) 7 (12.7) 72 71.3)
ABI Ankle-brachial index, DPA Dorsalis pedis artery, PAD Peripheral arterial
disease, TPA Tibialis posterior artery
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HEMO studies of patients on HD, a diagnosis of PAD
was based on a previous PAD diagnosis, the presence
of intermittent claudication or critical ischemia of the
extremities, previous surgical revascularization or am-
putation as a consequence of PAD, and prior diagno-
sis of an abdominal aortic aneurysm. Based on these
criteria, the rates of PAD in the DOPPS and HEMO
studies were 25.3 and 23%, respectively [8, 12].
Likewise, the prevalence of PAD in the NHANES was
24% in the group of patients with chronic kidney dis-
ease, and the same criteria were used to diagnose
PAD [10].
In studies that used ABI < 0.9 as a criterion for PAD
diagnosis in patients on HD, PAD prevalence was slightly
higher and it reached 37% [6]. Because ABIs < 0.9 are rele-
vant for a diagnosis of PAD, they are an important prog-
nostic factor associated with cardiovascular disease and
mortality in patients on HD [11, 16, 19].
In our study, PAD was associated with older age, DM,
and anemia, and a high percentage of patients with PAD
had hypertension; however, the rate of left ventricular
hypertrophy was not significantly higher in this group of
patients, perhaps because it was determined by electro-
cardiography. Significant differences did not exist with
respect to the systolic and diastolic blood pressure
values determined before and after HD nor in relation to
the pulse pressure and mean arterial pressure values in
this study, but other investigators have described signifi-
cantly higher diastolic and pulse pressure values in pa-
tients with PAD on HD [12, 13]. Viazzi et al. [3]
suggested that the predictive power associated with am-
bulatory interdialytic blood pressure monitoring was
much greater than the predictive powers of blood pres-
sure measurements attained in the clinic or those deter-
mined immediately before and after dialysis. Our
patients on HD were closely monitored and their blood
pressure was well controlled, regardless of the presence
of PAD.
Fig. 2 The median ankle-brachial index values in the hemodialysis
patients with and without peripheral arterial disease. X title: PAD, w/
o PAD. Y title: ABI value
Table 3 Biochemical characteristics of the study population
Total PAD No PAD P
Urea, mmol/l 23.1 ± 4.7 23.3 ± 5.1 22.9 ± 4.4 0.663
Creatinine, μmol/l 840 ± 164 837 ± 182 841 ± 155 0.878
Albumin, g/L 37 ± 2 36 ± 2 38 ± 2 0.005
Glucose, mmol/l 6.4 ± 1.9 7.0 ± 2.1 6.0 ± 1.7 0.002
Total cholesterol, mmol/l 4.2 ± 1.0 4.0 ± 0.8 4.4 ± 1.1 0.024
Triglyceride, mmol/l 1.83 ± 0.93 1.82 ± 1.07 1.83 ± 0.85 0.934
Erythrocytes, × 1012/L 3.42 ± 0.30 3.41 ± 0.29 3.43 ± 0.30 0.663
Hemoglobin, g/dL 10.4 ± 0.9 10.3 ± 0.8 10.4 ± 1.0 0.373
Iron, μmol/l mean ± SD 10.9 ± 3.3 9.9 ± 3.0 11.5 ± 3.3 0.004
T-Sat.,% median (range) 0.29 (0.08–7.49) 0.28 (0.08–0.54) 0.29 (0.15–7.49) 0.064
Ferritin, ng/mL median (range) 279 (28–1126) 285 (44–906) 274 (28–1126) 0.201
White blood cell, ×109/L 7.05 ± 2.25 7.47 ± 2.19 6.82 ± 2.26 0.086
CRP, mg/L median (range) 7.3 (0.4–104.3) 9.7 (0.9–104.3) 6.6 (0.4–64.9) < 0.001
K, mean ± SD 5.22 ± 0.98 5.20 ± 1.40 5.24 ± 0.65 0.775
Calcium, mmol/l 2.27 ± 0.17 2.26 ± 0.15 2.27 ± 0.17 0.732
Phosphorus, mmol/l 1.50 ± 0.42 1.51 ± 0.43 1.48 ± 0.41 0.74
Parathormone, pg/ml, median (range) 131 (6.1–4184) 123 (14.6–1564.6) 140 (6.1–4184.0) 0.292
CRP C-reactive protein, PAD Peripheral arterial disease, T-sat Transferrin saturation
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Several authors have described higher frequencies of
cardiovascular disease and stroke among patients with
PAD [5, 22]. Although the patients in this study had
high rates of cardiovascular disease and stroke, the
groups did not differ with regard to their frequencies.
Anemia was present among patients with PAD, a finding
that concurs with the findings from a previously pub-
lished study that showed that patients with PAD with
anemia had a more severe form of the disease and had
higher risks of mortality and limb amputation than pa-
tients with PAD without anemia [23].
Whereas the traditional risk factors associated with
PAD, namely, age, DM, smoking status, hypertension,
male sex, and hyperlipidemia [8], are valid within the gen-
eral population, the risk factors for PAD slightly differ
among patients on HD [6, 13]. In addition to the trad-
itional risk factors, renal-specific factors are associated
with PAD in patients on HD [6, 12, 13]. A smaller number
of studies have investigated correlations between PAD and
its risk factors in patients on HD [24]. The findings from
the HEMO study that included 936 patients on HD,
showed that DM, age, and smoking status are associated
with PAD, while the other conventional risk factors,
namely, male sex, hypertension, and hypercholesterolemia,
are not associated with PAD [9].
The findings from the United States Renal Data Sys-
tem study and the Dialysis Morbidity and Mortality
Study, which examined the associations among the vari-
ables related to dialysis and the conventional cardiovas-
cular risk factors for PAD in patients on dialysis, showed
that a diagnosis of PAD was associated with age, male
sex, being Caucasian, DM, smoking status, higher dia-
stolic blood pressure, and left ventricular hypertrophy.
In an adjusted analysis, PAD was also associated with
low serum parathyroid hormone levels, a longer dialysis
vintage, a lower Kt/V, and a low serum albumin level
[25]. Compared with the non-PAD group, the HD vin-
tage was shorter in the PAD group in this study, but the
difference was not significant, which concurs with the
findings from a study carried out in Japan [12]; however,
other investigators consider that PAD is related to the
dialysis vintage [14]. Lower Kt/V values were observed
among patients in the PAD group, which is consistent
with the findings from other studies [11, 25]. These
findings might help explain why some uremic toxins that
are not removed by dialysis, for example, dimethylargi-
nine, accumulates, damages endothelial cells, and causes
atherogenesis [19].
Chronic uremia is associated with systemic inflamma-
tion that causes hypoalbuminemia and increases the
risk of PAD [13, 26], and may play an important role in
the pathogenesis and progression of atherosclerosis
[13]. Chronic inflammation, malnutrition, and hyper-
phosphatemia are associated with PAD in patients with
end-stage renal disease [6, 7]. The serum albumin and
total cholesterol levels indicate not only a patient’s nu-
tritional status but also chronic inflammation [25, 26].
Serum CRP is related not only to vascular inflammatory
reactions but also promotes atherogenesis and athero-
thrombosis [27]. In this study, patients with PAD had
significantly higher CRP levels and lower albumin, total
cholesterol, and iron levels, which are indirect indica-
tors of malnutrition, inflammation, and atherosclerosis
syndrome [28].
Similar to our study, several investigators have shown
that hyperlipidemia is not a risk factor for PAD in pa-
tients on HD [12, 29], but some authors have described
hyperlipidemia as a risk factor for PAD [5, 11]. In con-
trast, the findings from one study indicated that hyper-
lipidemia had a protective effect against PAD [29].
The patients with PAD in our study had significantly
higher levels of glycemia, which correlated with the
higher incidence of diabetes in these patients. Several
authors have described DM and poor glycemic control
as important risk factors for PAD [5, 8, 13, 26]. Earlier
reports have suggested that inflammation plays a key
Table 4 Logistic regression analyses using peripheral arterial disease as the dependent variable
Univariate model Multivariate model
Independent variable OR (95% CI) P OR (95% CI) P
Age 1.04 (1.01–1.07) 0.004 1.01 (0.97–1.06) 0.536
Diabetes mellitus 2.85 (1.35–6.00) <0.001 1.29 (0.48–3.51) 0.817
Anemia 0.15 (0.02–1.21) 0.074 0.31 (0.03–3.00) 0.313
PAD symptoms by Fontaine 6.55 (3.55–12.1) <0.001 5.20 (2.60–10.4) <0.001
Access Hickman 4.74 (1.39–16.2) 0.013 4.66 (1.03–21.0) 0.045
Kt/v 0.36 (0.13–1.06) 0.064 1.04 (0.27–4.07) 0.953
Albumin 0.84 (0.74–0.96) 0.008 1.04 (0.88–1.25) 0.627
Total cholesterol 0.64 (0.43–0.94) 0.023 0.83 (0.50–1.37) 0.462
CRP 1.04 (1.02–1.07) 0.002 1.03 (1.00–1.06) 0.030
CRP C-reactive protein, PAD Peripheral arterial disease
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role in atherosclerosis and confirmed that patients with
elevated CRP and lower albumin levels have high occur-
rence rates of PAD [27]. The findings from this study
concur with those from previous studies.
A distal radiocephalic AVF is the vascular access of
choice for HD at our center because it is associated with
the longest survival times and the lowest number of
complications. Patients with inadequate blood vessels
undergo AVG implantations. Tunneled Hickman vascu-
lar catheters are used for permanent vascular access in
patients who have poor prognoses and shorter life ex-
pectancies and whose blood vessels are inappropriate for
an AVF or AVG implantations [30]. Our data showed
that compared with the patients without Hickman vas-
cular catheters (25%), a significantly higher number of
patients on HD with Hickman vascular catheters had
PAD (75%). We also observed that patients with PAD
and Hickman vascular catheter had significantly lower
hemoglobin (p = 0.001), and albumin (p = 0.022) levels
than patients with AVF. Compared to the patients with
AVF, patients with implanted Hickman vascular catheter
and AVG had significantly higher CRP values (p = 0.05).
The presence of a permanent vascular catheter was a
predictor of PAD, and the use of the catheter may be as-
sociated with silent or overt inflammation. As is already
known, there is a strong correlation between the athero-
sclerosis of blood vessels of the arm and PAD. Moreover,
an increased incidence of vascular access failure was
noted in patients with AVG compared to those with
AVF [16, 31].
The management and treatment of patients with PAD
requires a multidisciplinary approach [32]. The National
Kidney Foundation’s Kidney Disease Outcomes Quality
Initiative guidelines [33] recommend that at the begin-
ning of a dialysis session, all patients should be screened
for PAD, be clinically examined, and have their ABIs
measured. These patients often have insufficient daily
activity and diabetic neuropathy, and they are usually
asymptomatic; due to this, they are underdiagnosed and
undertreated [12, 20].
Once PAD is diagnosed, all risk factors must be rigor-
ously managed, which includes smoking cessation,
administering aspirin, statins, and cilostazol, and under-
taking active exercise [19, 22]. Timely diagnosis of PAD
and its early treatment can improve patients’ quality of
life and avoid or, at least, delay undesirable events, in-
cluding amputation or death [12, 13].
Study limitations
This was a single-center study that involved a relatively
small number of patients. Additionally, for the purposes
of vascular access, ABI was calculated based on the sys-
tolic blood pressure that was measured on one side only,
which may have affected the findings as a consequence
of subclavian steal syndrome and underestimated the
values in some patients. We evaluated left ventricular
hypertrophy based on electrocardiography, and we did
not perform echocardiography. Although we determined
the total cholesterol and triglyceride values, there were
no data that described the high- and low-density lipo-
protein cholesterol levels. We performed a cross-sec-
tional study of prevalent patients on HD; however, a
long-term study that monitors the relationships between
the risk factors and the development of PAD in incident
patient’s, would generate more robust data.
Conclusion
The prevalence of PAD was high in our group of pa-
tients on HD. Independent predictors of PAD were the
presence of symptoms based on the Fontaine classifica-
tion, a higher CRP level, and vascular access provided by
a Hickman catheter for HD. An ABI < 0.9 combined
with the clinical findings and claudication more accur-
ately signifies clinically significant PAD. An ABI < 0.9
alone, without clinical findings, is not sufficient for the
detection of clinically significant PAD in patients on HD.
Adequate and timely diagnosis and treatment of PAD
could improve the quality of life and postpone complica-
tions in these patients.
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